Two preclinical biotechs riding the IPO wave this week look to raise $466M-plus; Blackstone's Galakatos backs Reata to the tune of $350M
→ These days, there’s virtually no raise too big for biotech. Case in point: 2 looming IPOs where the executive team is sketching out some …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
